(Q43754356)

English

Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3.

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Effects of low-dose pravastatin on plasma levels of lipids and apolipoproteins in Japanese type II hyperlipoproteinemic subjects with apolipoprotein E phenotype E3/2, E3/3, and E4/3. (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

author name string

Kobayashi T

1

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Homma Y

2

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

language of work or name

1 reference

based on heuristic

inferred from title

publication date

1 October 2001

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

The Journal of Clinical Pharmacology

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

41

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

10

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

1055-1058

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

The influence of apolipoprotein E phenotype on the response to lovastatin therapy in patients with heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

Efficacy and safety of pravastatin in patients with primary hypercholesterolemia. I. A dose-response study

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

Intestinal cholesterol absorption efficiency in man is related to apoprotein E phenotype

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

Dietary fat clearance in normal subjects is regulated by genetic variation in apolipoprotein E.

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

Apolipoprotein-E phenotype and basal activity of low-density lipoprotein receptor are independent of changes in plasma lipoprotein subfractions after cholesterol ingestion in Japanese subjects

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

LDL particle size distribution. Results from the Framingham Offspring Study

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

Influence of apo E polymorphism on the response to simvastatin treatment in patients with heterozygous familial hypercholesterolemia

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

The response to lovastatin treatment in patients with heterozygous familial hypercholesterolemia is modulated by apolipoprotein E polymorphism

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

Effect of apolipoprotein E and A-IV phenotypes on the low density lipoprotein response to HMG CoA reductase inhibitor therapy

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

Dose-dependent hypolipidemic effect of an inhibitor of HMG-CoA reductase, pravastatin (CS-514), in hypercholesterolemic subjects. A double blind test

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

Quantitation of serum apolipoprotein A-I, A-II, B, C-II, C-III and E in healthy Japanese by turbidimetric immunoassay: reference values, and age- and sex-related differences

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

Effects of simvastatin on apoB metabolism and LDL subfraction distribution

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

Effects of simvastatin on plasma lipoprotein subfractions, cholesterol esterification rate, and cholesteryl ester transfer protein in type II hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

Specific reduction of plasma large, light low-density lipoprotein by a bile acid sequestering resin, cholebine (MCI-196) in type II hyperlipoproteinemia

1 reference

https://api.crossref.org/works/10.1177%2F00912700122012643

21 January 2018

Identifiers

10.1177/00912700122012643

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43754356&oldid=2103056396"